home · filing · 0001140361-21-032255
8-K filed September 23, 2021, 7:59 PM ET
ticker ERNA
CIK 0000748592
leadership
confidence high
sentiment neutral
materiality 0.55
Brooklyn ImmunoTherapeutics appoints CMO Roger Sidhu, outlines gene editing strategy; appoints Marcum as auditor
Ernexa Therapeutics Inc.
Roger Sidhu appointed CMO effective Sept 20, 2021; receives option for 161,300 shares and RSU for 80,650 shares, base salary $447,200.
Bylaws amended to remove CFO position; VP of Finance Sandra Gurrola serves as principal financial officer.
Marcum LLP appointed as new independent auditor for FY2021 after dismissal of Baker Tilly.
Shareholder update call: plans to use iMSCs for allogeneic bone marrow transplants, gene editing for solid tumors and monogenic disorders.
Dr. Sidhu previously at Kite Pharma (Gilead), Roivant Sciences, Cell Design Labs, Amgen; M.D. from Queen's University.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2021-09-20
Filed September 23, 2021, 7:59 PM ET
On September 22, 2021, we announced that Roger Sidhu had been appointed as our Chief Medical Officer, effective September 20, 2021.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Roger Sidhu was appointed as Chief Medical Officer at Ernexa Therapeutics Inc..
Action appointed
Role Chief Medical Officer
Exact text from the filing
On September 22, 2021, we announced that Roger Sidhu had been appointed as our Chief Medical Officer, effective September 20, 2021.
View on SEC.gov
Source: SEC EDGAR
accession 0001140361-21-032255
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.